Synektik Sa · GPW:SNT
Synektik Sa — H1 FY2025 Earnings Presentation
23 slides from Synektik Sa's earnings presentation, June 2026
Slide 1: H1 FY 2025: Financial results
SYNEKTIK SA H1 FY 2025: Financial results Investor Presentation June 2026 H1 FY 2025 Financial results | Investor presentation 1
Slide 2: Synektik in snapshot
Synektik in snapshot WIG, mWIG40, Indexes WIGTECH, WIG-Poland ISIN PLSNKTK0001 441m 118m Number of shares 8 529 129 PLN PLN Capitalisation(1) PLN 2.38bn REVENUE FROM SALES, EBITDA FROM CONTINUING Enterprise value(2) PLN 2.40bn H1 FY2025 OPERATIONS, H1 FY2025 P/E(3) 15.5 EV/EBITDA(4) 11.2 Company pro
Slide 3: Highlights: Oct. 2025 – June 2026
Highlights: Oct. 2025 – June 2026 Sales of equipment and IT solutions – revenue growth and business expansion PLN 413.6 million in revenue (excluding intra-group transactions) in H1 FY2025 (36% year-on-year increase), including PLN 187.4 million in recurring revenue (29% YoY growth); segment EBITD
Slide 4: Financial performance in H1 FY2025 (PLN mln)
Financial performance in H1 FY2025 (PLN mln) Consolidated revenue 36% increase in total revenue from sales of equipment, IT solutions and H1 FY2025 441.2 services (excluding intra-group transactions) +35% H1 FY2024 327.8 17% increase in revenue of the radiopharmaceuticals segment, excluding intr
Slide 5: Financial performance in Q2 FY2025 (PLN mln)
Financial performance in Q2 FY2025 (PLN mln) Consolidated revenue 76% increase in total revenue from sales of equipment, IT solutions and Q2 FY2025 213.2 services (excluding intra-group transactions) +71% Q2 FY2024 124.7 19% increase in revenue of the radiopharmaceuticals segment, excluding intr
Slide 6: Group’s adjusted EBITDA in FY 2022-2025
Group’s adjusted* EBITDA in FY 2022-2025 Adjusted* EBITDA EBITDA growth driven by: (PLNm) 59.8 58.2 52.7 50.5 55.2 Growing scale of recurring sales in both 41.6 segments, characterized by attractive 31.7 31.7 33.8 margins 29.8 30.4 24.9 24.9 Increase in sales of equipment used in 10.9 therapy Q1
Slide 7: Group’s recurring sales in FY 2022-2025
Group’s recurring sales in FY 2022-2025 Recurring revenue for past 4 quarters Dynamic growth of recurring revenue (PLNm) Drivers: 39.2 37.5 Dynamically increasing demand for consumable 35.8 parts and accessories for therapy equipment sold 35.0 by the Synektik Group Revenue from sales of radiopharm
Slide 8: Selected financial data
Selected financial data PLN 000s Q2 FY 2025 Q2 FY 2024 H1 FY 2025 H1 FY 2024 Sales revenue 213 186 124 694 441 162 327 822 PLN 261.3 million accounting profit on the spin-off, EBIT* 53 718 25 406 107 690 71 061 recognized in net profit and total comprehensive EBIT margin* 25.2% 20.4% 24.4% 21.7% E
Slide 9: Medical equipment and IT solutions
SYNEKTIK SA Medical equipment and IT solutions H1 FY 2025 Financial results | Investor presentation 9
Slide 10: Medical equipment and IT solutions: Key information
Medical equipment and IT solutions Key information Synektik is a leading provider of medical equipment and IT solutions used in radiology, oncology, cardiology and neurology Core areas: Sale of medical equipment from several leading manufacturers, used in radiology, therapy and nuclear medicine
Slide 11: Medical equipment and IT solutions: Financial results
Medical equipment and IT solutions Financial results (PLN million) Growing business profitabiity 413.6 36% increase in sales (year-over-year) in H1 FY 2025, up to PLN 413.6 million 304.3 46% increase in EBITDA in H1 FY 2025, up to PLN 121.0 million, increase in EBITDA 121.0 segment profitability
Slide 12: Promising outlook for the second half of the year
Medical equipment and IT solutions Promising outlook for the second half of the year Sales of medical equipment, orders for implementation and active offers (in PLN million) Secured orders worth PLN 311 million in H1 FY 2025 The value of active offers as of the end of March 2026 is PLN 165.3 mil
Slide 13: Commercialization of da Vinci system
Medical equipment and IT solutions Commercialization of da Vinci system Da Vinci assisted surgical procedures in Poland, Czech Republic and Slovakia (number) 11000 122 10000 Approximately 6.4 k surgeries with the assistance of da Vinci in Q2 FY 2025 in Poland (up 30% y/y) 9000 Approximately 4.0
Slide 14: Da Vinci serviced by GK Synektik
Medical equipment and IT solutions Gdynia Da Vinci serviced by GK Synektik Gdańsk Grudziądz Wejherowo Słupsk Olsztyn 132 92 Szczecin Białystok Bydgoszcz Włocławek Toruń Wieliszew Biała Podlaska Grodzisk da Vinci systems serviced da Vinci systems Gorzów Wlkp. Maz. by GK Synektik in Poland* Poznań War
Slide 15: Radiopharmaceuticals
SYNEKTIK SA Radiopharmaceuticals H1 FY 2025 Financial results | Investor presentation 15
Slide 16: Radiopharmaceuticals: Key information
Radiopharmaceuticals Key information Synektik is the largest producer and supplier of PET/CT radiopharmaceuticals in Poland 55+ Number of 3 Production sites together employees with R&D Centre Major producer of special radiopharmaceuticals Location of cyclotrons for the production of radiopharmac
Slide 17: Radiopharmaceuticals: Growing revenues and profits
Radiopharmaceuticals Growing revenues and profits Financial results (PLN million) 27.5 PLN 27.5 million in revenue in H1 FY 2025, up 17% YoY 23.6 15% growth in basic tracer sales, to all-time high PLN 14.5 million 7.7 8.7 32% growth in special tracer sales, to PLN 6.3 million PLN 8.7 million
Slide 18: Cardiac-tracer
SYNEKTIK SA Cardiac-tracer H1 FY 2025 Financial results | Investor presentation 18
Slide 19: Synektik S.A. spin-off
Synektik S.A. spin-off Summary: ▪ A part of Synektik SA related to the following areas was transferred to Syn2bio SA in exchange for newly issued shares: ▪ the search for new innovative pharmaceutical molecules, as well as their further research, registration, and introduction to the market as a med
Slide 20: Dividends
SYNEKTIK SA Dividends H1 FY 2025 Financial results | Investor presentation 20
Slide 21: Dividends
Dividends Synektik S.A. Dividend history 10.75 Growth in dividend potential thanks to increasing scale and division 8.25 102.6 ▪ Synektik has paid a dividend to shareholders every year since 2020 (the first for FY 2018). 82.5 ▪ In February 2026 the company paid out a record 3.03 dividend for FY 2024
Slide 22: Q&A Session
SYNEKTIK SA Q&A SESSION H1 FY 2025 Financial results | Investor presentation 22
Slide 23: Thank you!
Cezary Kozanecki Thank you! President of the Management Board, CEO ckozanecki@synektik.com.pl Dariusz Korecki Vice-President of the Management Board, CFO dkorecki@synektik.com.pl